X4 Pharmaceuticals, Inc. (XFOR)

4.07 +0.03 (+0.74%) USD  |  NASDAQ  |  Sep 01, 16:00
4.07 0.00 (0.00%) After-Hours: 17:23
More

X4 Pharmaceuticals Total Long Term Debt (Quarterly) : 76.76M for June 30, 2026

Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for XFOR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 76.76M
March 31, 2026 76.52M
December 31, 2025 76.29M
September 30, 2025 76.16M
June 30, 2025 76.66M
March 31, 2025 76.74M
December 31, 2024 76.84M
September 30, 2024 76.98M
June 30, 2024 77.06M
March 31, 2024 57.14M
December 31, 2023 57.18M
September 30, 2023 57.17M
June 30, 2023 35.72M
March 31, 2023 35.76M
December 31, 2022 37.22M
September 30, 2022 37.15M
June 30, 2022 37.24M
March 31, 2022 37.71M
December 31, 2021 38.71M
September 30, 2021 38.80M
June 30, 2021 38.89M
Date Value
March 31, 2021 38.94M
December 31, 2020 37.66M
September 30, 2020 30.21M
June 30, 2020 26.84M
March 31, 2020 26.95M
December 31, 2019 22.02M
September 30, 2019 22.13M
June 30, 2019 28.27M
March 31, 2019 21.94M
December 31, 2018 9.832M
September 30, 2018 10.74M
June 30, 2018 11.19M
March 31, 2018 12.02M
December 31, 2017 12.24M
September 30, 2017 12.52M
June 30, 2017 12.69M
March 31, 2017 12.05M
December 31, 2016 12.43M
September 30, 2016 0.00
June 30, 2016 0.00
March 31, 2016 0.00

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Sarepta Therapeutics, Inc. 1.046B
Arrowhead Pharmaceuticals, Inc. 1.371B
Oncolytics Biotech, Inc. 0.31M
Sangamo Therapeutics, Inc. 19.33M
Anixa Biosciences, Inc. 0.14M